Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SHILPAMED

SHILPA MEDIC

HealthcarePharmaceuticals & Biotechnology₹17917 cr market cap
₹900.70 ▼ -1.6% today As of 19 Nov 2026
52-week low ₹267.0052-week high ₹1073.70

-14.8% from the 52-week high · +242.8% above the low

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka and currently employs 2,731 full-time employees. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The firm's product range includes oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

The short version. SHILPA MEDIC reported revenue of ₹529 crore for Sep 2026, up 43.0% from a year earlier. Net profit was ₹79 crore (up 79.5% year on year). Return on equity was 9.4% in Mar 2026. Promoter holding was 40.13% in Sep 2026, down 4.10 points over 8 quarters.

1 · The price

How has the stock traded?

SHILPA MEDIC trades 14.8% below its 52-week high and 242.8% above its 52-week low.

Change over period: —

1M+4.5%
3M+13.3%
6M+92.2%
1Y+150.6%

2 · The business

Is it growing?

Sales, year on year+43.0%

Sep 2026 revenue of ₹529 cr.

Profit, year on year+79.5%

Sep 2026 net profit of ₹79 cr.

Net margin15.0%

3.1 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue529466437410370321331319
Net profit791011084544471532
Net margin %15.021.724.710.911.914.64.410.0
EPS (₹)4.055.165.512.282.252.40.741.63

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue15391286115210501146901908733
Net profit2437832-3261148156112
Net margin %15.86.12.8-3.15.316.417.215.3
EPS (₹)12.444.01.84-1.873.499.069.586.88

3 · The quality

How well does it turn capital into profit?

Return on equity was 9.4% in Mar 2026; debt to equity is 0.25.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %9.43.31.8-1.8
Return on capital %12.47.56.31.1
EBITDA margin %30.623.822.311.2
Net margin %15.76.02.8-3.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR13.2%10.7%
Profit CAGR—10.5%
Debt to equity0.25
Interest cover6.0x
Current ratio1.31
P/E ratio64.5

4 · The owners

Who holds it, and are they adding?

Promoter holding40.13%

Down 4.1 pts over 8 quarters.

Foreign institutions12.11%

Up 2.21 pts over 8 quarters.

Domestic institutions8.26%

Down 0.01 pts over 8 quarters.

Mutual fund schemes33

+12 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter44.2344.2344.2344.2340.1340.1340.1340.13-4.1
FII9.910.9711.210.9210.9711.0811.3812.11+2.21
DII8.277.557.467.678.338.588.058.26-0.01
Public37.637.2537.1137.1840.5640.2140.4339.49+1.89

Mutual fund holdings · Oct 2026

33 schemes hold this stock

21 the month before.

  • SAMCO SPECIAL OPPORTUNITIES FUND3.47% of NAV
  • UNION FOCUSED FUND3.26% of NAV
  • Bandhan Healthcare Fund3.09% of NAV
  • SAMCO ACTIVE MOMENTUM FUND3.03% of NAV
  • HDFC Pharma and Healthcare Fund2.92% of NAV
  • UNION ACTIVE MOMENTUM FUND2.51% of NAV
  • UNION SMALL CAP FUND1.88% of NAV
  • ICICI Prudential Exports and Services Fund1.5% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SHILPA MEDIC are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SHILPA MEDIC

What is the SHILPA MEDIC share price?

SHILPA MEDIC (SHILPAMED) last closed at ₹900.70, down 1.6% on the day. Its 52-week range is ₹267.00 to ₹1,073.70.

What is the market cap of SHILPA MEDIC?

SHILPA MEDIC has a market capitalisation of about ₹17,917 crore. Its price-to-earnings ratio is 64.5.

How are SHILPA MEDIC's latest results?

SHILPA MEDIC reported revenue of ₹529 crore for Sep 2026, up 43.0% from a year earlier. Net profit was ₹79 crore (up 79.5% year on year). Return on equity was 9.4% in Mar 2026. Promoter holding was 40.13% in Sep 2026, down 4.10 points over 8 quarters.

Who owns SHILPA MEDIC?

As of Sep 2026, shareholding was: Promoter 40.13%, FII 12.11%, DII 8.26%, Public 39.49%.

How many mutual funds hold SHILPA MEDIC?

33 mutual fund schemes held SHILPA MEDIC in October 2026. That compares with 21 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 03 Oct 2025 · Bonus issue 1:1
  • 17 Sep 2025 · Final Dividend - Rs. 1
  • 19 Sep 2022 · Dividend - Rs. 1.1
  • 20 Sep 2021 · Dividend - Rs. 1.1
  • 16 Mar 2020 · Interim Dividend - Rs. 1.1
  • 12 Sep 2019 · Dividend - Rs. 1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.